We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Globus Medical (GMED) Closes Alphatec Buyout, Stock Gains
Read MoreHide Full Article
Globus Medical, Inc. (GMED - Free Report) , a medical devices company specializing in musculoskeletal implants, recently completed the acquisition of Alphatec Holdings, which was announced in July. Headquartered in Carlsbad, CA, Alphatec is a publicly traded medical device company that provides spinal fusion technologies and spinal devices.
Following the announcement, shares of Globus Medical rallied 2.1% to close at $23.97. However, a thorough analysis of the current market trends reveal that the sentiments are not impressive for Globus Medical as it represents a modest one-year return of 2.5%, much lower than the S&P 500’s 13.4% over the same time frame. However, we believe that the recent development will to-some-extent help the company overcome the current unfavorable situation.
Post the closing of Alphatec buyout for $80 million in cash, Globus Medical has gained complete control over Alphatec’s international operations and distributor sales channel. Earlier, the company also agreed to extend a 5-year senior secured credit facility of up to $30 million to Alphatec to support their working capital needs.
Globus Medical is highly optimistic about this deal which according to the company will meaningfully boost its international expansion. The company allying with Alphatech, should gain access to Alphatech’s existing markets in Japan and foray into other emerging markets. In this regard we note that Globus Medical recorded an 8.1% year-over-year increase in international sales in the just-reported second quarter of fiscal 2016.
Management is also quite hopeful, as the purchase is expected to be ‘marginally accretive’ in 2017 and represent incremental adjusted earnings of up to 8 cents per share in 2018 and beyond.
Our Take
A glimpse at the global trends reveals that the spinal implants and devices market is expected to reach a worth of $15.7 billion by 2020, growing at a CAGR of 5.6%, as per Markets And Markets.
Buoyed by such trends, we believe Alphatec would help Globus Medical gain traction and fortify its market position.
Zacks Rank and Key Picks
Currently, Globus Medical has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Natus Medical Inc. , Masimo Corporation (MASI - Free Report) and IDEXX Laboratories Inc. (IDXX - Free Report) . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Globus Medical (GMED) Closes Alphatec Buyout, Stock Gains
Globus Medical, Inc. (GMED - Free Report) , a medical devices company specializing in musculoskeletal implants, recently completed the acquisition of Alphatec Holdings, which was announced in July. Headquartered in Carlsbad, CA, Alphatec is a publicly traded medical device company that provides spinal fusion technologies and spinal devices.
Following the announcement, shares of Globus Medical rallied 2.1% to close at $23.97. However, a thorough analysis of the current market trends reveal that the sentiments are not impressive for Globus Medical as it represents a modest one-year return of 2.5%, much lower than the S&P 500’s 13.4% over the same time frame. However, we believe that the recent development will to-some-extent help the company overcome the current unfavorable situation.
Post the closing of Alphatec buyout for $80 million in cash, Globus Medical has gained complete control over Alphatec’s international operations and distributor sales channel. Earlier, the company also agreed to extend a 5-year senior secured credit facility of up to $30 million to Alphatec to support their working capital needs.
Globus Medical is highly optimistic about this deal which according to the company will meaningfully boost its international expansion. The company allying with Alphatech, should gain access to Alphatech’s existing markets in Japan and foray into other emerging markets. In this regard we note that Globus Medical recorded an 8.1% year-over-year increase in international sales in the just-reported second quarter of fiscal 2016.
GLOBUS MEDICAL Price
GLOBUS MEDICAL Price | GLOBUS MEDICAL Quote
Management is also quite hopeful, as the purchase is expected to be ‘marginally accretive’ in 2017 and represent incremental adjusted earnings of up to 8 cents per share in 2018 and beyond.
Our Take
A glimpse at the global trends reveals that the spinal implants and devices market is expected to reach a worth of $15.7 billion by 2020, growing at a CAGR of 5.6%, as per Markets And Markets.
Buoyed by such trends, we believe Alphatec would help Globus Medical gain traction and fortify its market position.
Zacks Rank and Key Picks
Currently, Globus Medical has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Natus Medical Inc. , Masimo Corporation (MASI - Free Report) and IDEXX Laboratories Inc. (IDXX - Free Report) . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>